首页 > 抗体蛋白 > 抗体
Alexa Fluor® 647 anti-human/mouse CD49f Antibo
产品名称:
Alexa Fluor® 647 anti-human/mouse CD49f Antibo
产品类别:
抗体
产品编号:
313609
产品应用:
313609
[价格]
规格 价格 库存
25tests ¥ 1416 1

产品详情

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Mouse, Baboon, Capuchin Monkey, Cat, Cow, Chimpanzee, Cynomolgus, Dog, Horse, Rabbit, Sheep, Pig
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse mammary tumor cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor? 647 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

* Alexa Fluor? 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm.


Alexa Fluor? and Pacific Blue? are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,5, in vitro and in vivo blocking of cell binding to laminin and blocking the function of integrin a61,4, and immunohistochemistry of acetone-fixed frozen sections2,3,5. The GoH3 antibody has been reported to block laminin binding in vitro and to block integrin a6 function in vivo.

Application References

(PubMed link indicates BioLegend citation)
  1. Georas SN, et al. 1993. Blood 82:2872. (IP, Block)
  2. Honda T, et al. 1995. J. Clin. Endocrinol. Metab. 80:2899. (IHC)
  3. Sonnenberg A, et al. 1986. J. Histochem. Cytochem. 34:1037. (IHC)
  4. Nakamura K, et al. 1997 Biochem. Biophys. Res. Commun. 235:524. (Block)
  5. Sonnenberg A, et al. 1987 J. Biol. Chem. 262:10376. (IP, IHC)
  6. Deregibus MC, et al. 2007. Blood doi:10.1182/blood-2007-03-078709.
  7. Horwitz KB, et al. 2008. Proc Natl Acad Sci USA. 105:5774. PubMed
  8. Nardella C, et al. 2009. Sci Signal. 2:55. PubMed
  9. Xu T, et al. 2010. Mol Cancer Ther. 9:438. PubMed
  10. Stepp MA, et al. 2007. J Cell Sci. 120:2851. PubMed
  11. Jo M, et al. 2010. Cancer Res. 70:8948. PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Grange C, et al. 2011. Cancer Res. 71:5346. PubMed
  14. Lai KP, et al. 2012. Mol Endocrinol. 26:52. PubMed
  15. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. (FC) PubMed
Product Citations
  1. Rostoker R, et al. 2015. Endocr Relat Cancer. 22:145. PubMed
  2. Byrd KM, et al. 2020. Cell Stem Cell. 25(6):814-829.e6.. PubMed
  3. Murai K, et al. 2022. Nat Commun. 13:6206. PubMed
  4. Yu L, et al. 2020. Cell Stem Cell. 28(3):550-567.e12. PubMed
  5. Wei X, Orjalo A, Xin L 2016. Stem Cell Res. 16: 597-606. PubMed
  6. Kwon O, et al. 2016. Stem Cell Res. 16: 682-691. PubMed
  7. Liu Y, et al. 2020. Cell Reports. 30(3):771-782.e6.. PubMed
  8. Kwon O, et al. 2014. Proc Natl Acad Sci U S A. 111:592. PubMed
  9. Xu T, et al. 2010. Mol Cancer Ther. 24:2164. PubMed
  10. Campbell J, et al. 2011. PLoS One. 6:e25661. PubMed
  11. Su Q, et al. 2016. Oncogene. 10.1038/onc.2016.232. PubMed
  12. Basak P, et al. 2015. Endocr Relat Cancer. 22: 505 - 517. PubMed
  13. Huang Y, et al. 2015. J Biol Chem. 290: 17745 - 17752. PubMed
  14. Huang Y, et al. 2015. J Biol Chem. 290: 17753 - 17761. PubMed
  15. Nardella C, et al. 2009. Sci Signal. 2:ra2. PubMed
  16. Park J, et al. 2016. Proc Natl Acad Sci U S A. 113: 4482-4487. PubMed
  17. Inoue N, et al. 2020. Development. 147:00:00. PubMed
  18. Murai K et al. 2018. Cell stem cell. 23(5):687-699 . PubMed
  19. Villarreal-Ponce A, et al. 2020. Cell Rep. 33:108417. PubMed
  20. Stoyanova T, et al. 2013. Proc Natl Acad Sci U S A. 110:20111. PubMed
  21. Fernandez–Antoran D, et al. 2019. Cell Stem Cell. 25:329. PubMed
  22. Inoue N, et al. 2020. Development. . PubMed
  23. Sfakianos JP, et al. 2020. Nat Commun. 2.222222222. PubMed
  24. Rodrigues Toste de Carvalho AL, et al. 2021. Nat Protoc. 16:1802. PubMed
RRID
AB_493636 (BioLegend Cat. No. 313609) AB_493637 (BioLegend Cat. No. 313610)

Antigen Details

Structure
Integrin family, associates with β1 or β4, 120 kD
Distribution

Platelets, monocytes, T cells, placental trophoblasts, epithelial and endothelial cells

Function
Adhesion, receptor for laminin and kalinin; laminin binding to VLA-6 induces T cell co-stimulation for proliferation and activation
Ligand/Receptor
With integrin β1 (CD29) forms VLA-6, with integrin β4 (CD104) forms a6β4 integrin; laminin and kalinin are ligands for these receptors
Cell Type
Embryonic Stem Cells, Endothelial cells, Epithelial cells, Monocytes, Platelets, T cells
Biology Area
Cell Adhesion, Cell Biology, Immunology, Innate Immunity, Stem Cells
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Sonnenberg A, et al. 1990. J. Cell Biol. 110:2145.
2. Sonnenberg A, et al. 1990. J. Cell. Sci. 96:207.
3. Aumailley M, et al. 1990. Exp. Cell Res. 188:55.
4. Niessen CM, et al. 1994. Exp. Cell Res. 211:360.

Gene ID
16403 View all products for this Gene ID 3655 View all products for this Gene ID
UniProt
View information about CD49f on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线